Apomorphine still leads on speed as ropinirole finds its place

Veterinary teams weighing emesis options in dogs are getting a clearer picture of where apomorphine and ropinirole fit. A 2023 JAVMA study found ropinirole ophthalmic solution produced vomiting in 91.4% of 279 dogs with known or suspected toxin or foreign material ingestion, versus 95.6% reported for apomorphine, while gastric evacuation of expected material was similar between the two agents. More recent prospective data published in 2025, however, found IV apomorphine outperformed ropinirole in emergency presentations, with a 99% first-dose success rate versus 81%, a median time to first emesis of 1.6 minutes versus 8.6 minutes, and no need for antiemetic rescue compared with 37% of ropinirole-treated dogs. That randomized trial, conducted at 2 specialty referral hospitals from October 2021 through March 2023, enrolled 132 client-owned dogs with suspected or confirmed toxin or foreign body ingestion and excluded patients in whom emesis was contraindicated, such as caustic or volatile exposures, as well as dogs with ocular disease, prior antiemetic use, or certain neurologic or hepatic histories. Ropinirole remains notable as Clevor, the first FDA-approved emetic for dogs in the U.S., approved in June 2020 as an ophthalmic dopamine agonist. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the comparison is less about whether ropinirole works and more about where it fits in practice. The evidence suggests ropinirole is a viable option, especially when an FDA-approved, non-injectable product is useful, but apomorphine may still be the better choice when speed and first-dose reliability matter most, such as urgent toxicant or foreign body cases. Toxicology guidance also continues to stress that emesis should be selective, not routine, because induction carries real risks and is contraindicated in some patients and exposures. In the 2025 trial, dogs that did not vomit within 20 minutes received a second identical dose and were monitored for 40 minutes, underscoring how protocol details and rescue planning can affect workflow in busy ER settings. (todaysveterinarypractice.com)

What to watch: Expect more discussion around case selection, clinic protocols, and whether newer comparative data shift emergency hospitals back toward apomorphine-first workflows for rapid decontamination. Also worth watching: how antiemetic availability shapes those protocols, especially with Dechra’s FDA-approved maropitant injectable, Emeprev, expected through major veterinary distributors in early 2026; the product is positioned as a bioequivalent antiemetic option with benzyl alcohol to reduce injection pain in dogs and no refrigeration requirement, features that could matter when rescue therapy is needed after emesis induction. (pubmed.ncbi.nlm.nih.gov)